Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, made the following post on X:
“Patient with high-risk Smoldering Myeloma t(4;14) was enrolled in a trial, received aggressive treatment for 2 years, and achieved MRD negativity. After 3 years, M protein reappeared at the same level as when enrolled in the trial, with no evidence of end organ damage.
- Start Dara-RVd/ASCT
- Survillance monthly
- Surveillance Q3 Months
- Start lenalidomide.”
Source: Al-Ola A Abdallah/X